198 related articles for article (PubMed ID: 15833866)
1. Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva).
Chinnaiyan P; Huang S; Vallabhaneni G; Armstrong E; Varambally S; Tomlins SA; Chinnaiyan AM; Harari PM
Cancer Res; 2005 Apr; 65(8):3328-35. PubMed ID: 15833866
[TBL] [Abstract][Full Text] [Related]
2. Isoalantolactone Enhances the Radiosensitivity of UMSCC-10A Cells via Specific Inhibition of Erk1/2 Phosphorylation.
Fan Y; Weng Z; Gao H; Hu J; Wang H; Li L; Liu H
PLoS One; 2015; 10(12):e0145790. PubMed ID: 26716456
[TBL] [Abstract][Full Text] [Related]
3. Targeting DDX3 with a small molecule inhibitor for lung cancer therapy.
Bol GM; Vesuna F; Xie M; Zeng J; Aziz K; Gandhi N; Levine A; Irving A; Korz D; Tantravedi S; Heerma van Voss MR; Gabrielson K; Bordt EA; Polster BM; Cope L; van der Groep P; Kondaskar A; Rudek MA; Hosmane RS; van der Wall E; van Diest PJ; Tran PT; Raman V
EMBO Mol Med; 2015 May; 7(5):648-69. PubMed ID: 25820276
[TBL] [Abstract][Full Text] [Related]
4. Synergistic effects of methyl 2-cyano-3,11-dioxo-18beta-olean-1,-12-dien-30-oate and erlotinib on erlotinib-resistant non-small cell lung cancer cells.
Nottingham E; Mazzio E; Surapaneni SK; Kutlehria S; Mondal A; Badisa R; Safe S; Rishi AK; Singh M
J Pharm Anal; 2021 Dec; 11(6):799-807. PubMed ID: 35028186
[TBL] [Abstract][Full Text] [Related]
5. Selective activator of human ClpP triggers cell cycle arrest to inhibit lung squamous cell carcinoma.
Zhou LL; Zhang T; Xue Y; Yue C; Pan Y; Wang P; Yang T; Li M; Zhou H; Ding K; Gan J; Ji H; Yang CG
Nat Commun; 2023 Nov; 14(1):7069. PubMed ID: 37923710
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial of stereotactic body radiation therapy combined with erlotinib for patients with limited but progressive metastatic non-small-cell lung cancer.
Iyengar P; Kavanagh BD; Wardak Z; Smith I; Ahn C; Gerber DE; Dowell J; Hughes R; Abdulrahman R; Camidge DR; Gaspar LE; Doebele RC; Bunn PA; Choy H; Timmerman R
J Clin Oncol; 2014 Dec; 32(34):3824-30. PubMed ID: 25349291
[TBL] [Abstract][Full Text] [Related]
7. Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation.
Porta R; Sánchez-Torres JM; Paz-Ares L; Massutí B; Reguart N; Mayo C; Lianes P; Queralt C; Guillem V; Salinas P; Catot S; Isla D; Pradas A; Gúrpide A; de Castro J; Polo E; Puig T; Tarón M; Colomer R; Rosell R
Eur Respir J; 2011 Mar; 37(3):624-31. PubMed ID: 20595147
[TBL] [Abstract][Full Text] [Related]
8. Radiotherapy and erlotinib combined: review of the preclinical and clinical evidence.
Mehta VK
Front Oncol; 2012; 2():31. PubMed ID: 22645717
[TBL] [Abstract][Full Text] [Related]
9. Improved ATM kinase inhibitor KU-60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasion.
Golding SE; Rosenberg E; Valerie N; Hussaini I; Frigerio M; Cockcroft XF; Chong WY; Hummersone M; Rigoreau L; Menear KA; O'Connor MJ; Povirk LF; van Meter T; Valerie K
Mol Cancer Ther; 2009 Oct; 8(10):2894-902. PubMed ID: 19808981
[TBL] [Abstract][Full Text] [Related]
10. Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study.
Gomez DR; Tang C; Zhang J; Blumenschein GR; Hernandez M; Lee JJ; Ye R; Palma DA; Louie AV; Camidge DR; Doebele RC; Skoulidis F; Gaspar LE; Welsh JW; Gibbons DL; Karam JA; Kavanagh BD; Tsao AS; Sepesi B; Swisher SG; Heymach JV
J Clin Oncol; 2019 Jun; 37(18):1558-1565. PubMed ID: 31067138
[TBL] [Abstract][Full Text] [Related]
11. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
Rosell R; Carcereny E; Gervais R; Vergnenegre A; Massuti B; Felip E; Palmero R; Garcia-Gomez R; Pallares C; Sanchez JM; Porta R; Cobo M; Garrido P; Longo F; Moran T; Insa A; De Marinis F; Corre R; Bover I; Illiano A; Dansin E; de Castro J; Milella M; Reguart N; Altavilla G; Jimenez U; Provencio M; Moreno MA; Terrasa J; Muñoz-Langa J; Valdivia J; Isla D; Domine M; Molinier O; Mazieres J; Baize N; Garcia-Campelo R; Robinet G; Rodriguez-Abreu D; Lopez-Vivanco G; Gebbia V; Ferrera-Delgado L; Bombaron P; Bernabe R; Bearz A; Artal A; Cortesi E; Rolfo C; Sanchez-Ronco M; Drozdowskyj A; Queralt C; de Aguirre I; Ramirez JL; Sanchez JJ; Molina MA; Taron M; Paz-Ares L;
Lancet Oncol; 2012 Mar; 13(3):239-46. PubMed ID: 22285168
[TBL] [Abstract][Full Text] [Related]
12. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors.
Sequist LV; Waltman BA; Dias-Santagata D; Digumarthy S; Turke AB; Fidias P; Bergethon K; Shaw AT; Gettinger S; Cosper AK; Akhavanfard S; Heist RS; Temel J; Christensen JG; Wain JC; Lynch TJ; Vernovsky K; Mark EJ; Lanuti M; Iafrate AJ; Mino-Kenudson M; Engelman JA
Sci Transl Med; 2011 Mar; 3(75):75ra26. PubMed ID: 21430269
[TBL] [Abstract][Full Text] [Related]
13. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.
Mok TS; Wu YL; Thongprasert S; Yang CH; Chu DT; Saijo N; Sunpaweravong P; Han B; Margono B; Ichinose Y; Nishiwaki Y; Ohe Y; Yang JJ; Chewaskulyong B; Jiang H; Duffield EL; Watkins CL; Armour AA; Fukuoka M
N Engl J Med; 2009 Sep; 361(10):947-57. PubMed ID: 19692680
[TBL] [Abstract][Full Text] [Related]
14. CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
Reungwetwattana T; Nakagawa K; Cho BC; Cobo M; Cho EK; Bertolini A; Bohnet S; Zhou C; Lee KH; Nogami N; Okamoto I; Leighl N; Hodge R; McKeown A; Brown AP; Rukazenkov Y; Ramalingam SS; Vansteenkiste J
J Clin Oncol; 2018 Aug; ():JCO2018783118. PubMed ID: 30153097
[TBL] [Abstract][Full Text] [Related]
15. Prognostic implications of combining EGFR-TKIs and radiotherapy in Stage IV lung adenocarcinoma with 19-Del or 21-L858R mutations: A real-world study.
Liang S; Wang H; Zhang Y; Tian H; Li C; Hua D
Cancer Med; 2024 Apr; 13(8):e7208. PubMed ID: 38659399
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and survival outcomes of alectinib vs. crizotinib in ALK‑positive NSCLC patients with CNS metastases: A retrospective study.
Liu Q; Fu Y; Guo J; Fu C; Tang N; Zhang C; Han X; Wang Z
Oncol Lett; 2024 May; 27(5):224. PubMed ID: 38586212
[TBL] [Abstract][Full Text] [Related]
17. Clinical efficacy and safety of erlotinib combined with chemotherapy in the treatment of advanced pancreatic cancer: A meta-analysis.
Liu XY; Pan HN; Yu Y
World J Gastrointest Surg; 2024 Mar; 16(3):921-931. PubMed ID: 38577077
[TBL] [Abstract][Full Text] [Related]
18. Radiation pneumonitis after concurrent aumolertinib and thoracic radiotherapy in EGFR-mutant non-small cell lung cancer patients.
Yin H; Jia W; Yu J; Zhu H
BMC Cancer; 2024 Feb; 24(1):197. PubMed ID: 38347438
[TBL] [Abstract][Full Text] [Related]
19. Radiation-Induced Innate Neutrophil Response in Tumor Is Mediated by the CXCLs/CXCR2 Axis.
Zhang F; Mulvaney O; Salcedo E; Manna S; Zhu JZ; Wang T; Ahn C; Pop LM; Hannan R
Cancers (Basel); 2023 Dec; 15(23):. PubMed ID: 38067390
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
